CA-NONAME-SECURITY
15.12.2020 14:02:11 CET | Business Wire | Press release
Noname Security, the enterprise API security company, launched from stealth today with $25 million in funding from Lightspeed, Insight Partners and Cyberstarts. Noname is the only holistic security platform that lets enterprises see and secure managed and unmanaged APIs exposed by the organization, consumed by the organization or used internally, thereby eliminating the API security blind spots that exist in most businesses today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005410/en/
Digital transformation encourages companies to leverage APIs extensively to grow business and promote innovation. However, many have an underdeveloped API security strategy, which creates a major attack surface. Gartner has stated that "by 2022, API abuses will move from an infrequent to the most-frequent attack vector, resulting in data breaches for enterprise web applications."(*)
Noname provides an agentless security platform that gives enterprises a complete view into the activity and threats in their environment. Frictionless to deploy, Noname integrates with existing IT infrastructure and gives businesses visibility, security, and control over any API, whether on or off the corporate API gateways. With Noname, enterprises are able to gain the productivity benefits of using APIs without sacrificing security.
"Application security has a huge blind spot," said Oz Golan, CEO and co-founder of Noname. "A leaky API on T-Mobile’s website exposed customer data. The US Postal Service API vulnerability exposed personal information of 60 million users of its online service. The fact you cannot place agents on every application server, and you cannot trust network architecture to funnel all APIs through a single gateway, means we need a new approach. We built Noname to give enterprises complete visibility into all APIs in their environment without requiring an agent or relying on API gateways. We can stop APIs from compromising corporate assets, regardless of whether those APIs are managed by IT or not."
"Noname's holistic solution to API security is spot on. The breadth and depth of insights provided while being so easy to deploy is magic," said Joseph Tso, a leading banking CISO.
Founded in 2020, and headquartered in Palo Alto, California, with an office in Tel Aviv, the Noname team is composed of top engineering talent from Israel and experienced Silicon Valley technology leaders. Noname CEO and co-founder Oz Golan was Director of Engineering at NSO. He served with co-founder and CTO Shay Levi in the selective Unit 8200 of the Israeli Defense Forces, whose alumni also founded Check Point, Waze (acquired by Google) and Palo Alto Networks.
Gili Raanan, Cyberstarts founder, was the first to partner with Noname, while Guru Chahal, Partner at Lightspeed Venture Partners, and Thomas Krane, Principal at Insight Partners, joined to close the Series A round.
"The exponential growth of APIs introduces risk that most enterprises are not prepared to handle," said Gili Raanan of Cyberstarts. "Oz and Shay's strong vision combined with their decision to blend top Israeli engineering talent with sales and marketing executives from Cylance, Armis and NSO set them up for success."
"Noname presents a big opportunity to help enterprises navigate the uncharted territory of APIs in their environment," said Guru Chahal of Lightspeed Venture Partners. "We were impressed with how the team has really listened to their customers to deliver what businesses need. Customers especially liked the on-click frictionless deployment for API discovery and stopping unauthorized access to their applications."
"Our investment in Noname represents Insight’s commitment to partnering with the next generation of Israeli software ScaleUps," said Thomas Krane, Principal at Insight Partners. "Noname’s pure-play API security platform delivers on the long-awaited hope for true runtime application security and will enable enterprises to continue their digital transformation without sacrificing security. We are thrilled to partner with Oz, Shay, and the rest of the team to bring the Noname product to the global enterprise community."
To learn more about Noname visit: www.nonamesecurity.com
(*) Gartner, API Security: What You Need to Do to Protect Your APIs, Mark O’Neill, Dionisio Zumerle, et al., 28 August 2019.
About Noname Security
Noname Security eliminates API security blind spots and protects enterprises from data leakage, authorization issues, abuse, misuse and data corruption with no agents and no network modifications. Fortune 500 companies trust Noname's holistic API security platform to see and secure their APIs. Noname is a privately held company headquartered in Palo Alto, California, with an office in Tel Aviv. www.nonamesecurity.com
About Lightspeed Venture Partners
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, and Health sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 400 companies globally, including Snap, Nest, Nutanix, AppDynamics, MuleSoft, OYO, Guardant, StitchFix, and GrubHub. Lightspeed and its affiliates currently manage $10.5B across the global Lightspeed platform, with investment professionals and advisors in Silicon Valley, Israel, India, China, Southeast Asia and Europe. www.lsvp.com
About Insight Partners
Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than $30 billion in capital commitments. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all. www.insightpartners.com
About Cyberstarts
Cyberstarts is a venture capital firm focused on cybersecurity and is backed by successful cybersecurity entrepreneurs. Cyberstarts is a leading platform for amazing teams of entrepreneurs solving the next big pain points in the cybersecurity world. Cyberstarts founder, Gili Raanan, was the first investor in cybersecurity-focused companies like Armis, Adallom, Axis and Fireblocks. www.cyberstarts.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005410/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
